

**Supplemental
Digital Content 3 –
Table 2**

Suppl. Table 2. The number and percentage of drug-resistant mutations in patients

| Group | Subtype (total n=86) | | |
|------------------|----------------------|---------------------------|-------------|
| | CRF01_AE (n=64) | C/CRF07_BC/CRF08_BC (n=7) | B/B' (n=15) |
| NRTI | | | |
| M41L | 1 (1.6%) | 0 | 0 |
| E44A | 1 (1.6%) | 0 | 0 |
| A62V | 1 (1.6%) | 0 | 0 |
| K65R | 1 (1.6%) | 0 | 0 |
| D67N | 1 (1.6%) | 0 | 0 |
| T69N/S | 4 (6.3%) | 0 | 0 |
| V75L/M | 5 (7.8%) | 0 | 0 |
| <i>Y115K</i> § | 0 | 1 (14.3%) | 0 |
| F116Y | 1 (1.6%) | 0 | 0 |
| V118I* | 1 (1.6%) | 2 (28.6%) | 0 |
| Q151M | 1 (1.6%) | 0 | 0 |
| V179D* | 0 | 1 (14.3%) | 0 |
| M184I/V | 2 (3.1%) | 0 | 0 |
| <i>L210M/D/W</i> | 3 (4.7%) | 1 (14.3%) | 0 |
| <i>T215D/Y</i> | 1 (1.6%) | 1 (14.3%) | 0 |
| <i>K219D</i> | 0 | 1 (14.3%) | 0 |
| NNRTI | | | |
| <i>T69L</i> | 0 | 1 (14.3%) | 0 |
| L74I | 0 | 1 (14.3%) | 0 |
| V75I | 0 | 1 (14.3%) | 0 |
| <i>K101T/E</i> | 2 (3.1%) | 0 | 0 |
| V106I/V* | 1 (1.6%) | 0 | 2 (13.3%) |
| V108I | 0 | 0 | 1 (6.7%) |
| <i>E138D/A*</i> | 0 | 1 (14.3%) | 1 (6.7%) |
| Y181C | 1 (1.6%) | 0 | 0 |
| Y188L | 1 (1.6%) | 0 | 0 |
| <i>H221D</i> | 0 | 1 (14.3%) | 0 |
| <i>P225D</i> | 0 | 1 (14.3%) | 0 |
| <i>F227D</i> | 0 | 1 (14.3%) | 0 |
| PI | | | |
| M46I | 2 (3.1%) | 0 | 0 |
| A71T* | 0 | 0 | 2 (13.3%) |

Seven subjects had more than one mutations: Fj.Fz.12H080847(K65R and Y181C), Fj.Qz.37H081002 (V197D and V75I), Fj.Qz.56H081424 and Fj.Fz.57H081483 (A71T and V106I/V), Fj.Fz.60BH081486 (V118I and E138A), Fj.Fz.83H082018 (M41L and Y188L), and Fj.Fz.112BH081488 (V118I and H221D). § The italic and bold mutations indicated the highly unusual mutation at the position. * Drug-resistance polymorphism.